Prostate cancer diagnosis using 24 cores extended biopsy;Diagnóstico del cáncer de próstata mediante biopsia ampliada de 24 cilindros

Actas Urologicas Espanolas

Volumn 29, Issue 10, 2005, Pages 934-942

  Rodriguez Alonso A ^a   Gonzalez Blanco A ^a   Pita Fernandez S ^b   Suarez Pascual G ^a   Bonelli Martin C ^a   Lorenzo Franco, J ^a   Alvarez Fernandez J C ^a   Cuerpo Perez M A ^a  

^a Universidad de La Coruña   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Adenocarcinoma; Biopsy; Diagnosis; Prostate; Prostatic neoplasms

Indexed keywords

AGED; ARTICLE; HUMAN; MALE; METHODOLOGY; NEEDLE BIOPSY; PATHOLOGY; PROSTATE TUMOR; STATISTICS;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33645455106     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(05)73373-8     Document Type: Article

References (35)

1. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-75.
2. Terris MK. Prostate biopsy strategies: past, present, and future. Urol Clin North Am 2002;29(1):205-212.
3. Jones JS, Oder M, Zippe GD. Saturation prostate biopsy with periprostatic block can be performed in the office. J Urol 2002;168:2108-2110.
4. Rabets JC, Jones JS, Patel A, Zippe GD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004;172:94-97.
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271(5):368-374.
6. Ellis WJ, Chetner MP, Preston SD, Drawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;152:1520-1525.
7. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 1998;159:920-924.
8. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-1574.
9. Chan TY, Chan DY, Stutzman KL, Epstein JI. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?. J Urol 2001;166:2181-2184.
10. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-cores biopsy. J Urol 2004;171:1089-1092.
11. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166:86-92.
12. Fleshner N, Klotz L. Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology 2002;60(1):93-97.
13. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000;163:158-162.
14. Gil Martínez P, Allepuz Losa C, Gil Sanz MJ. Oliva Encina J, Andrés Lázaro V, Valdivia Navarro P, et al. Rebiopsia de próstata. Factores pronósticos del resultado anatomopatoló gico. Actas Urol Esp 2000;24(7):560-567.
15. Djavan B, Remzi M, Marberger M. When to biopsy and when to stop biopsying. Urol Clin North Am 2003;30(2): 253-262.
16. Roehl KA, Antenor JAV, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-2439.
17. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-157.
18. Eskew LA, Bare RL, McCullough. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-203.
19. Chen ME, Troncoso P, Johnston D, Tang K, Babaian RJ. Optimization of prostate biopsies using computer based analysis. J Urol 1997;158(6):2168-2175.
20. Stamey TA. Making the most out of six systematic biopsies. Urology 1995;45(1):2-12.
21. Morote J, López M, Encabo G, de Torres IM. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol 2000;37(5):537-540.
22. Schröder FH. Screening for prostate cancer. Urol Clin North Am 2003;30(2):239-251.
23. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275(4):288-294.
24. Bostwick DG, Graham SD Jr, Napalkov P, Abrahamsson PA, di Sant'agnese PA, Algaza F. Staging of early prostate cancer: a proponed tumor volume-based prognostic index. Urology 1993;41:403-411.
25. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS. Localizad prostate cancer. Cancer 1993;71(3): 933-938.
26. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0,5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003;170:370-372.
27. Levine MA, Ittman M, Melamed J. Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159:471-476.
28. Huland H, Graefen M, Haese A, Hammerer PG, Palisaar J, Pichlmeier U, et al. Prediction of tumor heterogeneity in localized prostate cancer. Urol Clin North Am 2002;29(1): 213-222.
29. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H. et al. Nonpalpable stage T1C prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-2411.
30. Gregori A, Vieweg J, Dahm P, Paulson DF. Comparison of ultrasound-guided biopsies and prostatectomy specimens: predictive accuracy of Gleason score and tumor site. Urol Int 2001;66(2):66-71.
31. Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomies specimens. Eur Urol 1998;33(3): 261-270.
32. Sokoloff, MH, Yang XJ, Fumo M, Mhoon D, Brendler CB. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/ml. BJU Int 2004;93:499-502.
33. Luján M, Paez A, Miravalles E, Fernández I, Llanes L, Berenguer A. Prostate cancer detection is also relevant in low prostate specific antigen ranges. Eur Urol 2004;45: 155-159.
34. Gardner TA, Lemer ML, Schlegel PN, Waldbaum RS, Vaughan ED Jr, Steckel J. Microfocal prostate cancer: biopsy cancer volume does not predict actual tumor volume. Br J Urol 1998;81:839-843.
35. Horninger W, Berger AP, Rogatsch H, Gschwendtner A, Steiner H, Niescher M, et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 2004;58:232-237.